Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Boehringer Ingelheim
Colorcon
Merck
Moodys
Baxter

Last Updated: November 22, 2019

DrugPatentWatch Database Preview

Litigation Details for Pfizer Inc. v. Wockhardt Limited (D. Del. 2009)

See Plans and Pricing

« Back to Dashboard

Pfizer Inc. v. Wockhardt Limited (D. Del. 2009)

Docket   Start Trial Date Filed 2009-04-29
Court District Court, D. Delaware Date Terminated 2012-07-24
Cause 35:271 Patent Infringement Assigned To Gregory Moneta Sleet
Jury Demand None Referred To
Parties CP PHARMACEUTICALS INTERNATIONAL CV; NORTHWESTERN UNIVERSITY; PFIZER INC.; WARNER LAMBERT COMPANY LLC; WOCKHARDT LIMITED; WOCKHARDT USA LLC
Patents 5,563,175; 6,001,876; 6,197,819
Attorneys Adam Gahtan; Brendan G. Woodard; Daniel M. Silver; Dimitrios T. Drivas; Jack B. Blumenfeld; Jeffrey J. Oelke; Kelly E. Farnan; R. Gregory Parker; Robert E. Counihan
Link to Docket External link to docket
Small Molecule Drugs cited in Pfizer Inc. v. Wockhardt Limited
The small molecule drugs covered by the patents cited in this case are   Start Trial and   Start Trial .

Details for Pfizer Inc. v. Wockhardt Limited (D. Del. 2009)

Date Filed Document No. Description Snippet Link To Document
2009-04-29 1 the expiration of United States Patent No. 6,197,819 (“the ‘819 patent”) Which covers Lyrica®. Case …Page|D #: 5 COUNT FOR INFRINGEMENT OF U.S. PATENT NO. 6,197,819 18. Plaintiffs reallege and incorporate…declaring that Wockhardt has infringed U.S. Patent No. 6,197,819; Case 1:09-cv-00312-GI\/|S Document 1 Filed…ACTION 1. This is an action for patent infringement under the patent laws of the United States, Title…1391 and 1400(b). THE PATENT-IN-SUIT ll. On March 6, 2001, the United States Patent and Trademark Office External link to document
2009-09-04 18 expiration of the ‘819 patent and U.S. Patent No. 5,563,175 (“the ‘ 175 patent”). Plaintiffs have filed…expiration of U.S. Patent Nos. 6,197,819 (“the ‘819 patent”) and 6,001,876 (“the ‘876 patent”). Plaintiffs … the expiration of the ‘ 819 patent, the ‘ 876 patent and the ‘175 patent. Plaintiffs have filed suit …alia, infringement of the ‘819 patent, the ‘876 patent and the ‘ 175 patent, WHEREAS, Defendants Actavis…the expiration of the ‘8 1 9 patent, the ‘876 patent and the ‘175 patent. Plaintiffs have filed suit in External link to document
2009-04-29 4 the Commissioner of Patents and Trademarks for Patent/Trademark Number(s) 6,197,819 B1; (dzs, ) (Entered…2009 24 July 2012 1:09-cv-00312 830 Patent None District Court, D. Delaware External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
AstraZeneca
Medtronic
Merck
Harvard Business School
McKesson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.